Clinical Trial Update: A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating vaccination with poly-ICLC and autologous dendritic cells in patients with non-resectable pancreatic adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Autologous dendritic cell vaccine (dendritic cell vaccine)
• Hiltonol (Poly-ICLC)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Pancreatic Adenocarcinoma Non-resectable | Phase 1 | Status: COMPLETED